Cell-Free DNA to Detect Heart Allograft Acute Rejection
Sean Agbor-Enoh, Palak Shah, Ilker Tunc, Steven Hsu, Stuart Russell, Erika Feller, Keyur Shah, Maria E Rodrigo, Samer S Najjar, Hyesik Kong, Mehdi Pirooznia, Ulgen Fideli, Alfiya Bikineyeva, Argit Marishta, Kenneth Bhatti, Yanqin Yang, Cedric Mutebi, Kai Yu, Moon Kyoo Jang, Charles Marboe, Gerald J Berry, Hannah A Valantine, GRAfT Investigators, Sean Agbor-Enoh, Palak Shah, Ilker Tunc, Steven Hsu, Stuart Russell, Erika Feller, Keyur Shah, Maria E Rodrigo, Samer S Najjar, Hyesik Kong, Mehdi Pirooznia, Ulgen Fideli, Alfiya Bikineyeva, Argit Marishta, Kenneth Bhatti, Yanqin Yang, Cedric Mutebi, Kai Yu, Moon Kyoo Jang, Charles Marboe, Gerald J Berry, Hannah A Valantine, GRAfT Investigators
Abstract
Background: After heart transplantation, endomyocardial biopsy (EMBx) is used to monitor for acute rejection (AR). Unfortunately, EMBx is invasive, and its conventional histological interpretation has limitations. This is a validation study to assess the performance of a sensitive blood biomarker-percent donor-derived cell-free DNA (%ddcfDNA)-for detection of AR in cardiac transplant recipients.
Methods: This multicenter, prospective cohort study recruited heart transplant subjects and collected plasma samples contemporaneously with EMBx for %ddcfDNA measurement by shotgun sequencing. Histopathology data were collected to define AR, its 2 phenotypes (acute cellular rejection [ACR] and antibody-mediated rejection [AMR]), and controls without rejection. The primary analysis was to compare %ddcfDNA levels (median and interquartile range [IQR]) for AR, AMR, and ACR with controls and to determine %ddcfDNA test characteristics using receiver-operator characteristics analysis.
Results: The study included 171 subjects with median posttransplant follow-up of 17.7 months (IQR, 12.1-23.6), with 1392 EMBx, and 1834 %ddcfDNA measures available for analysis. Median %ddcfDNA levels decayed after surgery to 0.13% (IQR, 0.03%-0.21%) by 28 days. Also, %ddcfDNA increased again with AR compared with control values (0.38% [IQR, 0.31-0.83%], versus 0.03% [IQR, 0.01-0.14%]; P<0.001). The rise was detected 0.5 and 3.2 months before histopathologic diagnosis of ACR and AMR. The area under the receiver operator characteristic curve for AR was 0.92. A 0.25%ddcfDNA threshold had a negative predictive value for AR of 99% and would have safely eliminated 81% of EMBx. In addition, %ddcfDNA showed distinctive characteristics comparing AMR with ACR, including 5-fold higher levels (AMR ≥2, 1.68% [IQR, 0.49-2.79%] versus ACR grade ≥2R, 0.34% [IQR, 0.28-0.72%]), higher area under the receiver operator characteristic curve (0.95 versus 0.85), higher guanosine-cytosine content, and higher percentage of short ddcfDNA fragments.
Conclusions: We found that %ddcfDNA detected AR with a high area under the receiver operator characteristic curve and negative predictive value. Monitoring with ddcfDNA demonstrated excellent performance characteristics for both ACR and AMR and led to earlier detection than the EMBx-based monitoring. This study supports the use of %ddcfDNA to monitor for AR in patients with heart transplant and paves the way for a clinical utility study. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02423070.
Keywords: allograft rejection; biomarkers; cardiac transplantation; cell-free DNA; graft injury.
Figures
![Figure 1:. Study design](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8221834/bin/nihms-1705528-f0001.jpg)
![Figure 2:. %ddcfDNA exponential decay early after…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8221834/bin/nihms-1705528-f0002.jpg)
![Figure 3:. Correlation %ddcfDNA measures with biopsy…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8221834/bin/nihms-1705528-f0003.jpg)
Figure 4:. Receiver operator characteristics curve for…
Figure 4:. Receiver operator characteristics curve for %ddcfDNA to detect endomyocardial biopsy-diagnosed acute rejection
a)…
Figure 5:. Distinct %ddcfDNA patterns in AMR…
Figure 5:. Distinct %ddcfDNA patterns in AMR and ACR
a – c %ddcfDNA against time…
- Solid Gold, or Liquid Gold?: Towards a New Diagnostic Standard for Heart Transplant Rejection.Kittleson MM, Garg S. Kittleson MM, et al. Circulation. 2021 Mar 23;143(12):1198-1201. doi: 10.1161/CIRCULATIONAHA.120.052925. Epub 2021 Mar 22. Circulation. 2021. PMID: 33750203 No abstract available.
- Response by Shah et al to Letter Regarding Article, "Cell-Free DNA to Detect Heart Allograft Acute Rejection".Shah P, Agbor-Enoh S, Tunc I, Hsu S, Russell S, Feller E, Shah K, Rodrigo ME, Najjar SS, Kong H, Pirooznia M, Fideli U, Bikineyeva A, Marishta A, Bhatti K, Yang Y, Mutebi C, Yu K, Kyoo Jang M, Marboe C, Berry GJ, Valantine HA; GRAfT (Genomic Research Alliance for Transplantation) Investigators. Shah P, et al. Circulation. 2021 Sep 7;144(10):e198-e199. doi: 10.1161/CIRCULATIONAHA.121.055697. Epub 2021 Sep 7. Circulation. 2021. PMID: 34491771 No abstract available.
- Letter by Amadio et al Regarding Article, "Cell-Free DNA to Detect Heart Allograft Acute Rejection".Amadio JM, Lafreniere-Roula M, McDonald M. Amadio JM, et al. Circulation. 2021 Sep 7;144(10):e196-e197. doi: 10.1161/CIRCULATIONAHA.121.054333. Epub 2021 Sep 7. Circulation. 2021. PMID: 34491772 No abstract available.
- Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study.Jang MK, Tunc I, Berry GJ, Marboe C, Kong H, Keller MB, Shah PD, Timofte I, Brown AW, Ponor IL, Mutebi C, Philogene MC, Yu K, Iacono A, Orens JB, Nathan SD, Agbor-Enoh S. Jang MK, et al. J Heart Lung Transplant. 2021 Aug;40(8):822-830. doi: 10.1016/j.healun.2021.04.009. Epub 2021 Apr 24. J Heart Lung Transplant. 2021. PMID: 34130911 Free PMC article.
- Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis.Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, Davis A, Shah P, Brown AW, Wang Y, Timofte I, Shah P, Gorham S, Wylie J, Goodwin N, Jang MK, Marishta A, Bhatti K, Fideli U, Yang Y, Luikart H, Cao Z, Pirooznia M, Zhu J, Marboe C, Iacono A, Nathan SD, Orens J, Valantine HA, Khush K. Agbor-Enoh S, et al. J Heart Lung Transplant. 2018 Jul;37(7):925-932. doi: 10.1016/j.healun.2018.01.1305. Epub 2018 Jan 31. J Heart Lung Transplant. 2018. PMID: 29500138
- Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).Keller M, Bush E, Diamond JM, Shah P, Matthew J, Brown AW, Sun J, Timofte I, Kong H, Tunc I, Luikart H, Iacono A, Nathan SD, Khush KK, Orens J, Jang M, Agbor-Enoh S. Keller M, et al. J Heart Lung Transplant. 2021 Jun;40(6):488-493. doi: 10.1016/j.healun.2021.02.008. Epub 2021 Feb 20. J Heart Lung Transplant. 2021. PMID: 33814284 Free PMC article.
- The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation.Gielis EM, Ledeganck KJ, Dendooven A, Meysman P, Beirnaert C, Laukens K, De Schrijver J, Van Laecke S, Van Biesen W, Emonds MP, De Winter BY, Bosmans JL, Del Favero J, Abramowicz D. Gielis EM, et al. Nephrol Dial Transplant. 2020 Apr 1;35(4):714-721. doi: 10.1093/ndt/gfz091. Nephrol Dial Transplant. 2020. PMID: 31106364
- The Monitoring of Donor-derived Cell-free DNA in Kidney Transplantation.Filippone EJ, Farber JL. Filippone EJ, et al. Transplantation. 2021 Mar 1;105(3):509-516. doi: 10.1097/TP.0000000000003393. Transplantation. 2021. PMID: 32732615 Review.
- Non-invasive detection of cardiac allograft rejection among heart transplant recipients using an electrocardiogram based deep learning model.Adedinsewo D, Hardway HD, Morales-Lara AC, Wieczorek MA, Johnson PW, Douglass EJ, Dangott BJ, Nakhleh RE, Narula T, Patel PC, Goswami RM, Lyle MA, Heckman AJ, Leoni-Moreno JC, Steidley DE, Arsanjani R, Hardaway B, Abbas M, Behfar A, Attia ZI, Lopez-Jimenez F, Noseworthy PA, Friedman P, Carter RE, Yamani M. Adedinsewo D, et al. Eur Heart J Digit Health. 2023 Jan 13;4(2):71-80. doi: 10.1093/ehjdh/ztad001. eCollection 2023 Mar. Eur Heart J Digit Health. 2023. PMID: 36974261 Free PMC article.
- Droplet digital PCR-based testing for donor-derived cell-free DNA in transplanted patients as noninvasive marker of allograft health: Methodological aspects.Clausen FB, Jørgensen KMCL, Wardil LW, Nielsen LK, Krog GR. Clausen FB, et al. PLoS One. 2023 Feb 24;18(2):e0282332. doi: 10.1371/journal.pone.0282332. eCollection 2023. PLoS One. 2023. PMID: 36827438 Free PMC article.
- A Novel Three-Dimensional Approach Towards Evaluating Endomyocardial Biopsies for Follow-Up After Heart Transplantation: X-Ray Phase Contrast Imaging and Its Agreement With Classical Histopathology.Planinc I, Ilic I, Dejea H, Garcia-Canadilla P, Gasparovic H, Jurin H, Milicic D, Skoric B, Stampanoni M, Bijnens B, Bonnin A, Cikes M. Planinc I, et al. Transpl Int. 2023 Jan 24;36:11046. doi: 10.3389/ti.2023.11046. eCollection 2023. Transpl Int. 2023. PMID: 36762268 Free PMC article.
- Current Status of Biomarkers and Molecular Diagnostic Tools for Rejection in Liver Transplantation: Light at the End of the Tunnel?El Sabagh A, Mohamed IB, Aloor FZ, Abdelwahab A, Hassan MM, Jalal PK. El Sabagh A, et al. J Clin Exp Hepatol. 2023 Jan-Feb;13(1):139-148. doi: 10.1016/j.jceh.2022.06.010. Epub 2022 Jun 30. J Clin Exp Hepatol. 2023. PMID: 36647415 Review.
- Diagnostic Potential of Minimally Invasive Biomarkers: A Biopsy-centered Viewpoint From the Banff Minimally Invasive Diagnostics Working Group.Huang E, Mengel M, Clahsen-van Groningen MC, Jackson AM. Huang E, et al. Transplantation. 2023 Jan 1;107(1):45-52. doi: 10.1097/TP.0000000000004339. Epub 2022 Dec 8. Transplantation. 2023. PMID: 36508645 Free PMC article. Review.
- Multicenter Study
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Adult
- Aged
- Allografts / transplantation*
- Cell-Free Nucleic Acids / genetics*
- Cohort Studies
- Female
- Graft Rejection / physiopathology*
- Humans
- Male
- Middle Aged
- Prospective Studies
- Young Adult
- Cell-Free Nucleic Acids
- ClinicalTrials.gov/NCT02423070
- Full Text Sources
- Other Literature Sources
- Medical
![Figure 4:. Receiver operator characteristics curve for…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8221834/bin/nihms-1705528-f0004.jpg)
![Figure 5:. Distinct %ddcfDNA patterns in AMR…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8221834/bin/nihms-1705528-f0005.jpg)
Source: PubMed